Barzi, Afsaneh

Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study

Ahn, D. H., Barzi, A., Ridinger, M., Samuëlsz, E., Subramanian, R. A., Wu, C.-C., Croucher, P. J. P., Smeal, T., Kabbinavar, F. F., & Lenz, H.-J. (2024) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 49

Telemedicine in Cancer Care Beyond the COVID-19 Pandemic: Oncology 2.0?

West, H., Barzi, A., & Wong, D. (2022) · Current Oncology Reports

Telemedicine and Telehealth ImplementationCOVID-19 and healthcare impacts

Cited by 45

A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)

Scott, A. J., Basu Mallick, A., Dotan, E., Cohen, S. J., Gold, P. J., Hochster, H. S., Subramaniam, S., Barzi, A., Watts, G. S., Blatchford, P. J., et al. (2022) · Cancer Research Communications

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 18

Single nucleotide polymorphisms in the IGF‐IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE‐3 trial

Schirripa, M., Zhang, W., Heinemann, V., Cao, S., Okazaki, S., Yang, D., Loupakis, F., Berger, M. D., Ning, Y., Miyamoto, Y., et al. (2017) · International Journal of Cancer

Colorectal Cancer Treatments and StudiesGrowth Hormone and Insulin-like Growth Factors

Cited by 11

436P Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer

Ahn, D. H., Erlander, M., Ridinger, M., Samuëlsz, E., Barzi, A., Bekaii-Saab, T., & Lenz, H. J. (2020) · Annals of Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 5